Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-214 inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral
01
Overview
miR-214 inhibitors are a class of therapeutic agents, typically antisense oligonucleotides or antagomirs, designed to bind and neutralize microRNA-214 (miR-214). miR-214 is a microRNA that is frequently overexpressed in various cancers, including melanoma, where it acts as an oncomiR by promoting cell invasion, migration, and metastasis. It achieves this by downregulating tumor-suppressive transcription factors such as TFAP2 and increasing the expression of adhesion molecules like ALCAM. By inhibiting miR-214, these agents aim to restore normal gene expression patterns and suppress the aggressive phenotype of tumor cells. Beyond oncology, miR-214 inhibition is also being explored for potential applications in treating fibrotic and cardiovascular diseases.
- Other names
- anti-miR-214anti-miR214anti-miR 214antagomir-214antagomir214antagomir 214microRNA-214 inhibitormicroRNA214 inhibitormicroRNA 214 inhibitormiRNA-214 inhibitormiRNA214 inhibitormiRNA 214 inhibitor
02
Targets
miR-214 (MicroRNA 214)
Beyond the preview
Go deeper on miR-214 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-214 inhibitor.